Latest results of large scale randomized phase III trials in advanced stage HL
One central question in Hodgkin lymphoma is the best treatment
for advanced stage patients. Initial data of the company-sponsored international ECHELON-1 trial were expected with substantial interest and will be presented at ASH 2017 in detail.
At ISHL11, this and more mature data for the combination of brentuximab vedotin (BV) and AVD will be discussed on the background of other clinical trials. The very recent results of the GHSG HD18 trial demonstrated that as few as 4 cycles of BEACOPPescalated are sufficient in advanced stage patients who are PET-negative after 2 initial cycles. The ongoing HD21 trial is investigating a BV-based adapted BEACOPP variant and trials investigating anti-PD1 antibodies in this setting are ongoing.